Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: Implications for trials of renal denervation

Hypertension

Volumn 65, Issue 2, 2015, Pages 401-406

  Patel, Hitesh C ^a,b   Hayward, Carl ^a,b   Ozdemir, Baris Ata ^c   Rosen, Stuart D ^b,d   Krum, Henry ^e   Lyon, Alexander R ^a,b   Francis, Darrel P ^b   Di Mario, Carlo ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d EALING HOSPITAL NHS TRUST   (United Kingdom)

^e MONASH UNIVERSITY   (Australia)

Author keywords

hypertension; meta analysis; placebos; randomized controlled trial

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO; ALISKIREN; AMIDE; AZILSARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOPYRAN DERIVATIVE; EPLERENONE; ETHANOLAMINE DERIVATIVE; FUMARIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; NEBIVOLOL; OLMESARTAN; OXADIAZOLE DERIVATIVE; SPIRONOLACTONE; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; CONTROL GROUP; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG RESISTANCE; INNERVATION; KIDNEY; META ANALYSIS; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACEBO EFFECT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; SYMPATHECTOMY; TREATMENT OUTCOME;

AMIDES; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOPYRANS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CONTROL GROUPS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; ETHANOLAMINES; FUMARATES; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY; OXADIAZOLES; PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RESEARCH DESIGN; SPIRONOLACTONE; SYMPATHECTOMY; TETRAZOLES; TREATMENT OUTCOME;

EID: 84921567556     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04640     Document Type: Article

References (22)

1. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
2. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomized controlled trial. Lancet. 2010;376:1903-1909.
3. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
4. de la Sierra A, Segura J, Banegas J, Gorostidi M, de la Cruz J, Armario P, Oliveras A, Ruilope L. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
5. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774.
6. de la Sierra A, Banegas J, Oliveras A, Gorostidi M, Segura J, de la Cruz J, Armario P, Ruilope L. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens. 2012;30:1211-1216.
7. R Core Team (2014). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. http://www. R-project. org/. Accessed July 2014.
8. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-773.
9. Whelton P, He J, Appel L, Cutler J, Havas S, Kotecha T, Roccella E, Stout R, Vallbona C, Winston M, Karimbakas J. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA. 2002;288:1882-1888.
10. Boehm M, Schlaich M, Narkiewicz K, Ruilope L, Williams B, Schmieder R, Mahfoud F, Mancia G. The blood pressure lowering effects of renal denervation in a real world population of patients with uncontrolled hypertension: early outcomes from the Global SYMPLICITY registry. Eur Heart J. 2013:34(1). doi: 10. 1093/ eurheartj/eht309. 3786.
11. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol. 2014;103:117-124.
12. Howard JP, Cole GD, Sievert H, Bhatt DL, Papademetriou V, Kandzari DE, Davies JE, Francis DP. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014;172:29-35.
13. Sassano P, Chatellier G, Corvol P, Menard J. Influence of observer's expectation on the placebo effect in blood pressure trials. Curr Ther Res. 1987;41:304-12.
14. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013;99:1579-1587.
15. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60:310-318.
16. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830.
17. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861.
18. Herttua K, Tabák AG, Martikainen P, Vahtera J, Kivimäki M. Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study. Eur Heart J. 2013;34:2933-2939.
19. Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have enhanced placebo effects? J Clin Epidemiol. 2000;53:786-792.
20. Grenfell R, Briggs A, Holland W. A double-blind study of the treatment of hypertension. J Am Med Assoc. 1961;176:124-128.
21. Goldring W, Chasis H, Schreiner GE, Smith HW. Reassurance in the management of benign hypertensive disease. Circulation. 1956;14:260-264.
22. Baker W, White M, Cappelleri J, Kluger J, Coleman C; From the Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract. 2009;63:1426-1434.